Ponatinib Evaluation And safety in Real Life CML patients failing ≥2 tyrosine kinase inhibitors: The PEARL observational study

Chronic myelogenous leukemia (CML) is induced by the onset of a unique molecular hit, the BCR-ABL oncogene, in a discrete population of hematopoietic stem cells and results in a considerable expansion of the myeloid compartment, compromised apoptotic process, recirculation of progenitors and genetic instability [1]. This chimeric oncogene is the consequence of a reciprocal translocation the t(9;22) (q34;q11), the Philadelphia chromosome [1]. The first tyrosine kinase inhibitor (TKI) imatinib mesylate, was introduced in 1998 and reversed the poor prognosis of this disease, particularly in chronic phase (CP) [2].

Source: Experimental Hematology - September 5, 2018 Category: Hematology Authors: Ma ël Heiblig, Delphine Rea, Marie-Lorraine Chrétien, Aude Charbonnier, Philippe Rousselot, Valérie Coiteux, Martine Escoffre-Barbe, Viviane Dubruille, Françoise Huguet, Emilie Cayssials, Eric Hermet, Agnès Guerci-Bresler, Shanti Amé, Lucila Sackman Source Type: research